Chromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell models
Molecular Biology Reports · 2024
DOI: 10.1007/s11033-024-09747-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Britta Stordal und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Natural Sciences, Middlesex University London, The Burroughs, Hendon, London, NW4 4BT, UK. b.stordal@mdx.ac.uk. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Mutation. Die Arbeit nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Irish Cancer Society, European Research Executive Agency.
Abstract (Originalsprache)
Background
The mutational status of ovarian cancer cell line IGROV-1 is inconsistent across the literature, suggestive of multiple clonal populations of the cell line. IGROV-1 has previously been categorised as an inappropriate model for high-grade serous ovarian cancer.
Methods
IGROV-1 cells were obtained from the Netherlands Cancer Institute (IGROV-1-NKI) and the MD Anderson Cancer Centre (IGROV-1-MDA). Cell lines were STR fingerprinted and had their chromosomal copy number analysed and BRCA1/2 genes sequenced. Mutation status of ovarian cancer-related genes were extracted from the literature.
Results
The IGROV-1-NKI cell line has a tetraploid chromosomal profile. In contrast, the IGROV-1-MDA cell line has pseudo-normal chromosomes. The IGROV-1-NKI and IGROV-MDA are both STR matches (80.7% and 84.6%) to the original IGROV-1 cells isolated in 1985. However, IGROV-1-NKI and IGROV-1-MDA are not an STR match to each other (78.1%) indicating genetic drift. The BRCA1 and BRCA2 gene sequences are 100% identical between IGROV-1-MDA and IGROV-1-NKI, including a BRCA1 heterozygous deleterious mutation. The IGROV-1-MDA cells are more resistant to cisplatin and olaparib than IGROV-1-NKI. IGROV-1 has a mutational profile consistent with both Type I ( PTEN, PIK3CA and ARID1A ) and Type II ovarian cancer ( BRCA1, TP53 ) and is likely to be a Type II high-grade serous carcinoma of the SET (Solid, pseudo-Endometroid and Transitional cell carcinoma-like morphology) subtype.
Conclusions
Routine testing of chromosomal copy number as well as the mutational status of ovarian cancer related genes should become the new standard alongside STR fingerprinting to ensure that ovarian cancer cell lines are appropriate models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Natural Sciences, Middlesex University London, The Burroughs, Hendon, London, NW4 4BT, UK. b.stordal@mdx.ac.uk.
- Department of Medical Oncology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland.
Förderung
- Irish Cancer Society
- European Research Executive Agency
Zitieren
APA
Stordal, B., Farrelly, A. M., & Hennessy, B. T. (2024). Chromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell models. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-09747-4
Vancouver
Stordal B, Farrelly AM, Hennessy BT. Chromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell models. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-09747-4
BibTeX
@article{Stordal2024,
author = {Stordal, Britta and Farrelly, Angela M and Hennessy, Bryan T},
title = {Chromosomal copy number and mutational status are required to authenticate ovarian cancer cell lines as appropriate cell models},
journal = {Molecular Biology Reports},
year = {2024},
doi = {10.1007/s11033-024-09747-4}
}
EUVIMED